Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 156
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 15  |  Issue : 3  |  Page : 263-272

Efficacy of synbiotic supplementation in improving rheumatoid arthritis


1 Rheumatology Clinic of the Internal Medicine Department, School of Medicine, Isfahan university of Medical Science, Isfahan, I.R. Iran
2 Department of Community Nutrition, School of Nutrition and Food Sciences, Isfahan university of Medical Science, Isfahan, I.R. Iran
3 Department of Epidemiology and Biostatistics, School of Health, Isfahan university of Medical Science, Isfahan, I.R. Iran
4 Department of Biology, Faculty of Science, University of Isfahan, Isfahan, I.R. Iran

Correspondence Address:
Mansour Salesi
Rheumatology Clinic of the Internal Medicine Department, School of Medicine, Isfahan university of Medical Science, Isfahan
I.R. Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1735-5362.288432

Rights and Permissions

Background and purpose: Today, improving rheumatoid arthritis (RA) as a chronic inflammatory disease is attributed to the proper status of the gut microbiota. Although some supplements containing beneficial live microorganisms (probiotics) can reduce inflammation by altering the bacterial composition of the gut, there is limited information on the effect of synbiotic (probiotics mixed with prebiotics) supplements on RA. Therefore, this study aimed to evaluate the anti-inflammatory effects of a synbiotic supplement as an adjuvant therapy in rheumatic patients. Moreover, for the first time, it was attempted to investigate whether addition of a synbiotic (1000 mg/day) to the combination of methotrexate and prednisolone increases the effectiveness of these antirheumatic drugs. Experimental approach: Eligible patients (186 subjects) were randomly divided into two groups. Both groups received their standard routine antirheumatic drugs, methotrexate and prednisolone. Moreover, the first group received a daily oral synbiotic supplement (1000 mg) for 3 months while the second group received a placebo. Various parameters indicating RA status were evaluated at baseline (time 0) and 3 months after the treatment. Findings / Results: The results showed the changes in the level of RA indicators, including tender joint count with a range of 0 to 28 joints, swollen joint count with a range of 0 to 28 joints, visual analog scale, erythrocyte sedimentation rate, CRP, and disease activity score based on 28 joints, after 3 months Conclusion and implications: Overall, no significant differences in the measured parameters were observed between synbiotic and placebo groups probably due to the short duration of the treatment period, and it is suggested to extend the treatment period to six months.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed153    
    Printed4    
    Emailed0    
    PDF Downloaded29    
    Comments [Add]    

Recommend this journal